Skip to main content
Top
Published in: Tumor Biology 10/2016

01-10-2016 | Original Article

Reprogramming bladder cancer cells for studying cancer initiation and progression

Authors: Banu Iskender, Kenan Izgi, Halit Canatan

Published in: Tumor Biology | Issue 10/2016

Login to get access

Abstract

The induced pluripotent stem cell (iPSC) technology is the forced expression of specific transcription factors in somatic cells resulting in transformation into self-renewing, pluripotent cells which possess the ability to differentiate into any type of cells in the human body. While malignant cells could also be reprogrammed into iPSC-like cells with lower efficiency due to the genetic and epigenetic barriers in cancer cells, only a limited number of cancer cell types could be successfully reprogrammed until today. In the present study, we aimed at reprogramming two bladder cancer cell lines HTB-9 and T24 using a non-integrating Sendai virus (SeV) system. We have generated six sub-clones using distinct combinations of four factors—OCT4, SOX2, KLF4 and c-MYC—in two bladder cancer cell lines. Only a single sub-clone, T24 transduced with 4Fs, gave rise to iPSC-like cells. Bladder cancer cell-derived T24 4F cells represent unique features of pluripotent cells such as epithelial-like morphology, colony-forming ability, expression of pluripotency-associated markers and bearing the ability to differentiate in vitro. This is the first study focusing on the reprogramming susceptibility of two different bladder cancer cell lines to nuclear reprogramming. Further molecular characterisation of T24 4F cells could provide a better insight for biomarker research in bladder carcinogenesis and could offer a valuable tool for the development of novel therapeutic approaches in bladder carcinoma.
Appendix
Available only for authorised users
Literature
8.
go back to reference Nishi M, Sakai Y, Akutsu H, Nagashima Y, Quinn G, Masui S, et al. Induction of cells with cancer stem cell properties from nontumourigenic human mammary epithelial cells by defined reprogramming factors. Oncogene. 2014;33(5):643–52. doi:10.1038/onc.2012.614. CrossRefPubMed Nishi M, Sakai Y, Akutsu H, Nagashima Y, Quinn G, Masui S, et al. Induction of cells with cancer stem cell properties from nontumourigenic human mammary epithelial cells by defined reprogramming factors. Oncogene. 2014;33(5):643–52. doi:10.​1038/​onc.​2012.​614.​ CrossRefPubMed
9.
go back to reference Borges GT, Vencio EF, Quek SI, Chen A, Salvanha DM, Vencio RZ, et al. Conversion of prostate adenocarcinoma to small cell carcinoma-like by reprogramming. J Cell Physiol. 2016. doi:10.1002/jcp.25313. PubMed Borges GT, Vencio EF, Quek SI, Chen A, Salvanha DM, Vencio RZ, et al. Conversion of prostate adenocarcinoma to small cell carcinoma-like by reprogramming. J Cell Physiol. 2016. doi:10.​1002/​jcp.​25313.​ PubMed
10.
13.
16.
17.
go back to reference Fernandez Tde S, de Souza Fernandez C, Mencalha AL. Human induced pluripotent stem cells from basic research to potential clinical applications in cancer. BioMed Res Int. 2013;2013:430290. doi:10.1155/2013/430290. PubMed Fernandez Tde S, de Souza Fernandez C, Mencalha AL. Human induced pluripotent stem cells from basic research to potential clinical applications in cancer. BioMed Res Int. 2013;2013:430290. doi:10.​1155/​2013/​430290.​ PubMed
18.
go back to reference Ron-Bigger S, Bar-Nur O, Isaac S, Bocker M, Lyko F, Eden A. Aberrant epigenetic silencing of tumour suppressor genes is reversed by direct reprogramming. Stem Cells. 2010;28(8):1349–54. doi:10.1002/stem.468. CrossRefPubMed Ron-Bigger S, Bar-Nur O, Isaac S, Bocker M, Lyko F, Eden A. Aberrant epigenetic silencing of tumour suppressor genes is reversed by direct reprogramming. Stem Cells. 2010;28(8):1349–54. doi:10.​1002/​stem.​468.​ CrossRefPubMed
19.
go back to reference Salci KR, Lee JH, Laronde S, Dingwall S, Kushwah R, Fiebig-Comyn A, et al. Cellular reprogramming allows generation of autologous hematopoietic progenitors from AML patients that are devoid of patient-specific genomic aberrations. Stem Cells. 2015;33(6):1839–49. doi:10.1002/stem.1994. CrossRefPubMedPubMedCentral Salci KR, Lee JH, Laronde S, Dingwall S, Kushwah R, Fiebig-Comyn A, et al. Cellular reprogramming allows generation of autologous hematopoietic progenitors from AML patients that are devoid of patient-specific genomic aberrations. Stem Cells. 2015;33(6):1839–49. doi:10.​1002/​stem.​1994.​ CrossRefPubMedPubMedCentral
20.
21.
go back to reference Giorgetti A, Montserrat N, Rodriguez-Piza I, Azqueta C, Veiga A, Izpisua Belmonte JC. Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2. Nat Protoc. 2010;5(4):811–20. doi:10.1038/nprot.2010.16. CrossRefPubMed Giorgetti A, Montserrat N, Rodriguez-Piza I, Azqueta C, Veiga A, Izpisua Belmonte JC. Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2. Nat Protoc. 2010;5(4):811–20. doi:10.​1038/​nprot.​2010.​16.​ CrossRefPubMed
22.
go back to reference Baxter MA, Camarasa MV, Bates N, Small F, Murray P, Edgar D, et al. Analysis of the distinct functions of growth factors and tissue culture substrates necessary for the long-term self-renewal of human embryonic stem cell lines. Stem Cell Res. 2009;3(1):28–38. doi:10.1016/j.scr.2009.03.002. CrossRefPubMed Baxter MA, Camarasa MV, Bates N, Small F, Murray P, Edgar D, et al. Analysis of the distinct functions of growth factors and tissue culture substrates necessary for the long-term self-renewal of human embryonic stem cell lines. Stem Cell Res. 2009;3(1):28–38. doi:10.​1016/​j.​scr.​2009.​03.​002.​ CrossRefPubMed
25.
go back to reference Iskender B, Izgi K, Sakalar C, Canatan H. Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway? Tumour Biol. 2015;37(2):1967–81.CrossRefPubMed Iskender B, Izgi K, Sakalar C, Canatan H. Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway? Tumour Biol. 2015;37(2):1967–81.CrossRefPubMed
27.
go back to reference Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G, et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet. 2009;41(9):968–76. doi:10.1038/ng.428. CrossRefPubMedPubMedCentral Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G, et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet. 2009;41(9):968–76. doi:10.​1038/​ng.​428.​ CrossRefPubMedPubMedCentral
29.
35.
go back to reference Lin SL, Chang DC, Chang-Lin S, Lin CH, DT W, Chen DT, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA. 2008;14(10):2115–24.CrossRefPubMedPubMedCentral Lin SL, Chang DC, Chang-Lin S, Lin CH, DT W, Chen DT, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA. 2008;14(10):2115–24.CrossRefPubMedPubMedCentral
40.
go back to reference Hoshino H, Nagano H, Haraguchi N, Nishikawa S, Tomokuni A, Kano Y, et al. Hypoxia and TP53 deficiency for induced pluripotent stem cell-like properties in gastrointestinal cancer. Int J Oncol. 2012;40(5):1423–30. doi:10.3892/ijo.2012.1346. PubMed Hoshino H, Nagano H, Haraguchi N, Nishikawa S, Tomokuni A, Kano Y, et al. Hypoxia and TP53 deficiency for induced pluripotent stem cell-like properties in gastrointestinal cancer. Int J Oncol. 2012;40(5):1423–30. doi:10.​3892/​ijo.​2012.​1346.​ PubMed
Metadata
Title
Reprogramming bladder cancer cells for studying cancer initiation and progression
Authors
Banu Iskender
Kenan Izgi
Halit Canatan
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5226-4

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine